Home › NDC Lookup › RxCUI directory › RxCUI 616578

Lubiprostone 0.024 MG Oral Capsule — RxCUI 616578

RxNorm drug concept · Semantic clinical drug
RxCUI 616578 Semantic clinical drug · SCD ● Current RxNorm concept 38 FDA products 73 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI616578
Official nameLubiprostone 0.024 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known aslubiprostone 24 MCG Oral Capsule
FDA products mapped38
Package NDCs mapped73
Reported Medicaid activity (SDUD)135,857 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Lubiprostone: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Lubiprostone is used to treat three types of constipation-related problems in adults: chronic idiopathic constipation (ongoing constipation with no clear cause), opioid-induced con...
  • Always take lubiprostone with food and water. Nausea is the most common complaint with this medicine, and taking it with a meal makes a real difference for most people. Swallow the...
  • Should I take this with food or on an empty stomach?
  • Nausea is the most frequently reported side effect, but for many people it improves over time or stays manageable when the capsule is taken with food. If nausea is really bothering...
📖 Read our full Lubiprostone guide →

🕸️ Concept Web — How Lubiprostone 0.024 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Lubiprostone 0.024 MG Oral Capsule RxCUI 616578

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Lubiprostone 623033
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Amitiza 615205
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Lubiprostone Oral Capsule 616577
    • Lubiprostone Oral Product 1163872
    • Lubiprostone Pill 1163873
    • Lubiprostone Oral Capsule [Amitiza] 617767
    • Amitiza Oral Product 1172836
    • Amitiza Pill 1172837
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Lubiprostone 0.024 MG SCDC · 616576
  • Lubiprostone Oral Capsule SCDF · 616577
  • Lubiprostone Oral Product SCDG · 1163872
  • Lubiprostone Pill SCDG · 1163873

Brand-Name Concepts

  • Lubiprostone 0.024 MG Oral Capsule [Amitiza] SBD · 617768
  • Lubiprostone 0.024 MG [Amitiza] SBDC · 617766
  • Lubiprostone Oral Capsule [Amitiza] SBDF · 617767
  • Amitiza Oral Product SBDG · 1172836
  • Amitiza Pill SBDG · 1172837
  • Amitiza BN · 615205

📦 FDA Products & Package NDCs

38 products · 73 package NDCs
73 package NDCs map to RxCUI 616578 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
72603-0288-01 60 CAPSULE in 1 BOTTLE (72603-288-01) Lubiprostone Northstar Rx LLC 2025-07-01
72603-0289-01 60 CAPSULE in 1 BOTTLE (72603-289-01) Lubiprostone Northstar Rx LLC 2025-07-01
76420-0777-01 100 CAPSULE in 1 BOTTLE (76420-777-01) Lubiprostone Asclemed USA, Inc. 2025-02-07
76420-0777-30 30 CAPSULE in 1 BOTTLE (76420-777-30) Lubiprostone Asclemed USA, Inc. 2025-02-07
76420-0777-60 60 CAPSULE in 1 BOTTLE (76420-777-60) Lubiprostone Asclemed USA, Inc. 2025-02-07
76420-0777-90 90 CAPSULE in 1 BOTTLE (76420-777-90) Lubiprostone Asclemed USA, Inc. 2025-02-07
76420-0778-01 100 CAPSULE in 1 BOTTLE (76420-778-01) Lubiprostone Asclemed USA, Inc. 2025-02-07
76420-0778-30 30 CAPSULE in 1 BOTTLE (76420-778-30) Lubiprostone Asclemed USA, Inc. 2025-02-07
76420-0778-60 60 CAPSULE in 1 BOTTLE (76420-778-60) Lubiprostone Asclemed USA, Inc. 2025-02-07
76420-0778-90 90 CAPSULE in 1 BOTTLE (76420-778-90) Lubiprostone Asclemed USA, Inc. 2025-02-07
76420-0906-01 100 CAPSULE, GELATIN COATED in 1 BOTTLE (76420-906-01) Lubiprostone Asclemed USA, Inc. 2025-01-28
76420-0906-30 30 CAPSULE, GELATIN COATED in 1 BOTTLE (76420-906-30) Lubiprostone Asclemed USA, Inc. 2025-01-28
76420-0906-60 60 CAPSULE, GELATIN COATED in 1 BOTTLE (76420-906-60) Lubiprostone Asclemed USA, Inc. 2025-01-28
76420-0906-90 90 CAPSULE, GELATIN COATED in 1 BOTTLE (76420-906-90) Lubiprostone Asclemed USA, Inc. 2025-01-28
76420-0907-01 100 CAPSULE, GELATIN COATED in 1 BOTTLE (76420-907-01) Lubiprostone Asclemed USA, Inc. 2025-01-28
76420-0907-30 30 CAPSULE, GELATIN COATED in 1 BOTTLE (76420-907-30) Lubiprostone Asclemed USA, Inc. 2025-01-28
76420-0907-60 60 CAPSULE, GELATIN COATED in 1 BOTTLE (76420-907-60) Lubiprostone Asclemed USA, Inc. 2025-01-28
76420-0907-90 90 CAPSULE, GELATIN COATED in 1 BOTTLE (76420-907-90) Lubiprostone Asclemed USA, Inc. 2025-01-28
80425-0355-02 60 CAPSULE, GELATIN COATED in 1 BOTTLE (80425-0355-2) Lubiprostone Advanced Rx of Tennessee, LLC 2023-08-16
82804-0001-30 30 CAPSULE, GELATIN COATED in 1 BOTTLE (82804-001-30) Lubiprostone Proficient Rx LP 2023-08-24
82804-0001-60 60 CAPSULE, GELATIN COATED in 1 BOTTLE (82804-001-60) Lubiprostone Proficient Rx LP 2023-08-24
82804-0001-90 90 CAPSULE, GELATIN COATED in 1 BOTTLE (82804-001-90) Lubiprostone Proficient Rx LP 2023-08-24
83008-0001-60 60 CAPSULE, GELATIN COATED in 1 BOTTLE (83008-001-60) Lubiprostone Quality Care Products, LLC 2023-03-14
Observed labelers: Proficient Rx LP (23) · Asclemed USA, Inc. (16) · SpecGx LLC (4) · Zydus Lifesciences Limited (4) · Zydus Pharmaceuticals USA Inc. (4) · American Health Packaging (2) · +12 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.